BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models

Eli Lilly’s and Boehringer Ingelheim’s Jardiance, approved by the FDA in 2014, is already a blockbuster in the treatment of Type 2 diabetes. But the companies have been aiming to get the drug approved to treat patients with heart failure who don't have diabetes, and they can now point to promising preclinical results in that indication.